Home  >  Products  >  EPM2A (epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) ) Blocking Peptide (the N terminal of EPM2A)(100ug)
EPM2A (epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) ) Blocking Peptide (the N terminal of EPM2A)(100ug)

EPM2A (epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) ) Blocking Peptide (the N terminal of EPM2A)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-EPM2A Antibody (ARP63376_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP63376
Size: 100ug
Weight: 35kDa
Gene: 7957
Format: Lyophilized powder
Target: This gene encodes a dual-specificity phosphatase that associates with polyribosomes. The encoded protein may be involved in the regulation of glycogen metabolism. Mutations in this gene have been associated with myoclonic epilepsy of Lafora. Alternative splicing results in multiple transcript variants.
Alternative names: EPM2; MELF
See Full Product Listings >